Argonaute and small RNAs in the nucleus: Mediators of gene silencing and activation

RNA molecules are dynamic regulators of gene expression, with duplex RNAs such as siRNAs and saRNAs functioning as versatile effectors that can both silence and activate gene expression through Argonaute (AGO) proteins. While cytoplasmic RNA interference (RNAi) is well established, the mechanisms and outcomes of nuclear RNAi and RNA activation (RNAa) are only emerging. This review integrates recent discoveries on nuclear RNAi and RNAa, outlining how siRNAs can target nuclear long noncoding RNAs, promoter-associated transcripts, and pre-mRNAs to mediate silencing, transcriptional repression, or alternative splicing. Conversely, saRNAs can recruit AGO2 and transcriptional cofactors to activate gene expression through chromatin remodeling and RNA polymerase II engagement. Beyond their mechanistic roles, we highlight the growing therapeutic potential of duplex RNAs, which can be harnessed to selectively silence or activate gene expression, offering new strategies for RNA-based precision medicine.

Authors

Institutions

Publication Details

Journal
Molecular Therapy — Nucleic Acids
Published
2026-04-22
DOI
https://doi.org/10.1016/j.omtn.2026.102938
Primary Topic
RNA Research and Splicing
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Argonaute and small RNAs in the nucleus: Mediators of gene silencing and activation

Annabelle Biscans, Aishe A. Sarshad, Evgeniia Shcherbinina, Michelle Fong
Molecular Therapy — Nucleic Acids
RNA Research and Splicing
article

Argonaute and small RNAs in the nucleus: Mediators of gene silencing and activation

Annabelle Biscans, Aishe A. Sarshad, Evgeniia Shcherbinina, Michelle Fong
article en

Abstract

RNA molecules are dynamic regulators of gene expression, with duplex RNAs such as siRNAs and saRNAs functioning as versatile effectors that can both silence and activate gene expression through Argonaute (AGO) proteins. While cytoplasmic RNA interference (RNAi) is well established, the mechanisms and outcomes of nuclear RNAi and RNA activation (RNAa) are only emerging. This review integrates recent discoveries on nuclear RNAi and RNAa, outlining how siRNAs can target nuclear long noncoding RNAs, promoter-associated transcripts, and pre-mRNAs to mediate silencing, transcriptional repression, or alternative splicing. Conversely, saRNAs can recruit AGO2 and transcriptional cofactors to activate gene expression through chromatin remodeling and RNA polymerase II engagement. Beyond their mechanistic roles, we highlight the growing therapeutic potential of duplex RNAs, which can be harnessed to selectively silence or activate gene expression, offering new strategies for RNA-based precision medicine.

Molecular Therapy — Nucleic AcidsVol. 37(2)
AstraZeneca (Finland) (FI), InDex Pharmaceuticals (Sweden) (SE), University of Gothenburg (SE)
Stiftelsen för Strategisk Forskning, Svenska Sällskapet för Medicinsk Forskning, Knut och Alice Wallenbergs Stiftelse, Vetenskapsrådet
Zero hunger
Openalex Percentile: Top 21%
RNA Research and Splicing
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.